Studies confirm regorafenib benefit in pre-treated metastatic colorectal cancer

Friday, July 3, 2015 - 12:00 in Health & Medicine

The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC), researchers. The safety profile and progression free survival were similar to phase III trial results.

Read the whole article on Science Daily

More from Science Daily

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net